Racial differences in hepatitis C treatment eligibility
Open Access
- 12 April 2011
- journal article
- viral hepatitis
- Published by Wolters Kluwer Health in Hepatology
- Vol. 54 (1) , 70-78
Abstract
: Black Americans are disproportionally infected with hepatitis C virus (HCV) and are less likely than whites to respond to treatment with peginterferon (PEG-IFN) plus ribavirin (RBV). The impact of race on HCV treatment eligibility is unknown. We therefore performed a retrospective analysis of a phase 3B multicenter clinical trial conducted at 118 United States community and academic medical centers to evaluate the rates of and reasons for HCV treatment ineligibility according to self-reported race. In all, 4,469 patients were screened, of whom 1,038 (23.2%) were treatment ineligible. Although blacks represented 19% of treated patients, they were more likely not to be treated due to ineligibility and/or failure to complete required evaluations (40.2%) than were nonblack patients (28.5%; P < 0.001). After the exclusion of persons not treated due to undetectable HCV RNA or nongenotype 1 infection, blacks were 65% less likely than nonblacks to be eligible for treatment (28.1% > 17.0%; relative risk, 1.65; 95% confidence interval, 1.46–1.87; P < 0.001). Blacks were more likely to be ineligible due to neutropenia (14% versus 3%, P < 0.001), anemia (7% versus 4%, P = 0.02), elevated glucose (8% versus 3%, P < 0.001), and elevated creatinine (5% versus 1%, P < 0.001). Conclusion: Largely due to a higher prevalence of neutropenia and uncontrolled medical conditions, blacks were significantly less likely to be eligible for HCV treatment. Increased access to treatment may be facilitated by less conservative neutrophil requirements and more effective care for chronic diseases, namely, diabetes and renal insufficiency. (HEPATOLOGY 2011;)Keywords
This publication has 42 references indexed in Scilit:
- Diabetes Care in Black and White Veterans in the Southeastern U.S.Diabetes Care, 2010
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- CKD Surveillance Using Laboratory Data From the Population-Based National Health and Nutrition Examination Survey (NHANES)American Journal of Kidney Diseases, 2009
- Racial Differences in the Evaluation and Treatment of Hepatitis C Among Veterans: A Retrospective Cohort StudyAmerican Journal of Public Health, 2008
- Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertensionHepatology, 2007
- Rate and predictors of treatment prescription for hepatitis CGut, 2006
- Barriers to Diabetes Education in Urban Patients Perceptions, Patterns, and Associated FactorsThe Diabetes Educator, 2005
- National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002Hepatology, 2002